OHM sales are continuing to grow but focus did shift towards...

First 6 Last

Share
Profile

Follow
McKhenry

726 Posts.

64

07/03/19

16:46

Post #: 37688626
Share

Originally posted by Colstone: ↑

If LIFX gets the nod then the current share price is incorrect.
Sure there are concerns around the tariff but there is a lot of positive information coming out from both the China and US atm and they have set a date towards the end of March on the agreement. obviously that date can shift and it's not in stone. But there is no need to set a date like that if no deal is done.
revenues are 44mil and half the shares in BUD are tied up until over 100mil revenues. Why would anyone do that if they didn't know something about their company.
Institutional investors were more than happy to provide more capital at 8 cents for the LIFX deal. They either just wanted to light a match and burn some money or they have more faith.
If you look at the whole picture Thor got renegotiated and those revenues should be back this quarter. tick.
OHM sales are continuing to grow but focus did shift towards this deal so that might underpin the quarter.
they have plenty of cash. Its a cheap play at 6.5 cents. As a pure risk reward trade you can prob buy it here and worst case stop at 3 or 4 cents in 9 months. But I doubt we see those levels.
DYOR

Expand

OHM sales are continuing to grow but focus did shift towards this deal so that might underpin the quarter.

With 3rd party sales channels, I cannot see that a lack of focus could cost sales, if we are needing the direct input to close sales from the MD and senior management, we are in strife. So will be calling BS if they pull that card.

BUD Price at posting: 6.4¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

ADD

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

HotCopper Highlights: Your most watched stocks for Week 48, 2024

RSG

Resolute shares bounce back as second payment made to Mali government to secure workers' release

There are more pages in this discussion • 5 more messages in this thread...

First 6 Last

Add BUD (ASX) to my watchlist

OHM sales are continuing to grow but focus did shift towards...

Top Stories

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

HotCopper Highlights: Your most watched stocks for Week 48, 2024

Resolute shares bounce back as second payment made to Mali government to secure workers' release

Featured News